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ABSTRACT 
Objectives. We evaluated the differential role of diabetes with insulin versus without insulin 
therapy on the thromboembolic risk in patients with atrial fibrillation (AF). 
Background. Diabetes is a known risk predictor for thromboembolic events in patients with AF, 
but no study has explored the prognostic weight of insulin-requiring versus non-insulin requiring 
diabetes in this setting.  
Methods. We accessed individual patients’ data from the prospective, real-world, multicenter, 
European Prevention of thromboembolic events-European Registry in Atrial Fibrillation (PREFER 
in AF). We compared the rates of stroke/systemic embolism at one year according to the diabetic 
status (no diabetes, diabetes without insulin therapy, diabetes on insulin therapy). 
Results: Out of an overall population of 5,717 patients, 1,288 had diabetes, 22.4% of whom were 
on insulin. Diabetes on insulin was associated with a significantly increased risk of stroke/systemic 
embolism at one year versus both no diabetes (5.2% versus 1.9%; HR 2.89, 95% CI 1.67-5.02; 
P=0.0002) and diabetes without insulin treatment (5.2% versus 1.8%; HR 2.96, 1.49-5.87; 
P=0.0019). Notably, rates of stroke/embolism were similar in patients with diabetes not receiving 
insulin versus non-diabetic patients (HR 0.97, 0.58-1.61; P=0.90). The selective predictive role of 
insulin-requiring diabetes was independent of potential confounders, including diabetes duration, 
and was maintained in various subpopulations, including the subgroup receiving anticoagulant 
therapy.  
Conclusions. In this cohort of anticoagulated patients with AF, the sole presence of diabetes not 
requiring insulin does not imply an increased thromboembolic risk. Conversely, insulin-requiring 
diabetes contributes most, if not exclusively, to the overall increase of thromboembolic risk in AF. 
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ABBREVIATIONS: 
 
AF= Atrial fibrillation 
CI= Confidence interval 
ENGAGE AF-TIMI 48= Effective Anticoagulation with Factor Xa Next Generation in Atrial 
Fibrillation–Thrombolysis in Myocardial Infarction 48  
HR= Hazard ratio 
PAI-1= Plasminogen activator inhibitor type 1 
PREFER= Prevention of thromboembolic events - European Registry 
tPA= Tissue-plasminogen activator  
VKA= Vitamin K antagonists  
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INTRODUCTION 
The evaluation of the thromboembolic risk is crucial in patients with atrial fibrillation (AF) in order 
to perform an accurate stratification of risk during follow-up and establish optimal therapeutic 
strategies. Diabetes mellitus has been considered an independent risk factor for thromboembolic 
events in AF patients (1), and this has led to inclusion of such parameter in the CHADS2 score (2) 
and the more recent CHA2DS2-VASc score (3). Patients with diabetes mellitus have a pro-
thrombotic state due to changes in primary (platelet aggregation and vascular function) and 
secondary (coagulation and fibrinolysis) hemostasis, and this is particularly enhanced in those with 
long-lasting disease receiving insulin therapy (4). Here, low-grade inflammation, increased levels of 
coagulation factors, impairment of fibrinolysis, oxidative stress and reduced expression of 
protective endothelial factors have been indicated as responsible for these prothrombotic changes 
(4). This is the basis for hypothesizing a stronger predictive role of diabetes requiring insulin 
therapy compared with less severe forms of diabetes, usually not requiring insulin, on the AF-
related thromboembolic risk. To date, no study has explored the differential prognostic weight of 
diabetes on insulin therapy vs diabetes without insulin therapy on the association between diabetes 
and thromboembolic events in patients with AF. We have explored this issue in a recent 
multicenter, European AF registry.    
 
METHODS 
We accessed individual patients’ data from the Prevention of thromboembolic events - European 
Registry in Atrial Fibrillation (PREFER in AF Registry) (5). PREFER in AF was a prospective, 
observational, real-world registry enrolling 7,228 AF patients from 461 hospitals in 7 European 
countries (Austria, France, Germany, Italy, Spain, Switzerland and United Kingdom). The first 
patient was enrolled in January 2012, and the last follow-up visit was done in January 2014. 
Inclusion criteria were: age ≥18 years; written informed consent to participate the study; history of 
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AF within the preceding 1 year, as demonstrated by an electrocardiogram or by an implanted 
pacemaker/defibrillator. Patients were included irrespective of the type of AF. In order to reduce 
selection bias, patients were consecutively enrolled at each site, with no explicit exclusion criteria. 
The study design consisted of a baseline clinical evaluation at the time of patient enrollment and at  
1-year follow-up. Demographic data, clinical characteristics, risk factors and treatment modalities 
were collected at baseline; at this time the documentation related to previous AF episodes and AF-
related antithrombotic therapy within 1 year was also inspected, if needed.  The follow-up was 
performed by office visit at 12±2 months. For the purpose of this study we only included patients 
with a complete CHA2DS2-VASc score evaluation and with both baseline and 1-year follow-up 
visits. Only documented stroke or systemic embolism were considered as relevant efficacy 
endpoints, with the date of any event being after the baseline visit. 
Individual data were entered into an electronic case report form including various 
plausibility checks for the considered variables. Furthermore, on-site verification of source data was 
performed in approximately 5% of the centers. The study management was overseen by a scientific 
Steering Committee; the registry was sponsored by Daiichi Sankyo Europe GmbH (Munich, 
Germany) via a contract research organization (SSS International Clinical Research GmbH – 
Munich, Germany) coordinating  various local national contract research organizations.    
Definitions and endpoints 
For the purpose of this study, diabetic patients were separately considered if they were or were not 
on insulin therapy (6). Primary study endpoint was the incidence of stroke/systemic embolism at the 
1-year follow-up according to the diabetes status (no diabetes, non-insulin requiring diabetes, 
insulin-requiring diabetes). Stroke and systemic embolism were defined following the Effective 
Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial 
Infarction 48 (ENGAGE AF-TIMI 48) definitions (7): Stroke: abrupt onset of a focal neurologic 
deficit, generally distributed in the territory of a single brain artery (including the retinal artery), and 
Patti G. et al., JACC070116-2744N-R2, page 6 
 
that is not attributable to an identifiable nonvascular cause (i.e., brain tumor or trauma). The deficit 
must either be characterized by symptoms lasting >24 hours or cause death within 24 hours of 
symptom onset. Stroke definition used in ENGAGE and in our study reflects the Statement for 
Healthcare Professionals From the American Heart Association/American Stroke Association (8), 
that incorporates the World Health Organization (WHO) definition of stroke (9). Systemic embolic 
event: abrupt episode of arterial insufficiency with clinical or radiologic documentation of arterial 
occlusion in the absence of other likely mechanisms (e.g., atherosclerosis, instrumentation); venous 
thromboembolism and pulmonary embolism were also included in this outcome measure. Arterial 
embolic events involving the central nervous system (including the eye) were not considered as 
systemic embolism.  
Statistics  
For categorical variables, absolute and percentage frequencies (n, %) are presented. For continuous 
variables, mean and standard deviation are presented. For the analyses of the time-to-
stroke/systemic embolism the Cox proportional hazard regression model was used, with diabetes 
status as fixed effect. The hazard ratio (HR), the 95% confidence interval (CI) and the 
corresponding p value are presented. These analyses were repeated for different subgroups of 
patients based on the demographic/clinical characteristics indicated in Table 1. In addition, these 
characteristics were added as single covariates to the model. Comparisons of all 
demographic/clinical characteristics for the diabetes status were executed by means of a logistic 
regression model presenting the odds ratio, the 95% confidence interval and the corresponding p 
value. All analyses are not confirmatory, but purely descriptive/exploratory. All statistical analyses 
were performed using SAS version 9.3. 
 
RESULTS 
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From the overall PREFER in AF population (N=7,228), a total of 816 patients had no one-year 
follow-up visit; therefore the full analysis set consisted of 6,412 patients, 695 of whom were 
excluded because of lack of information on stroke/systemic embolic event and/or no availability of  
CHA2DS2-VASc scoring and/or no information on diabetes status (Figure 1). Thus, a total of 5,717 
patients were included in this sub-analysis. Prevalence of thromboembolic risk factors and different 
anti-thrombotic therapies in patients included in this analysis was consistent with the overall 
PREFER in AF population (data not shown). Among those 5,717 patients, a total of 1,288 had 
diabetes mellitus (22.5%), 288 of whom were on insulin treatment (22.4%). Patients with diabetes, 
irrespective of the insulin therapy status, had an increased prevalence of systemic hypertension, 
congestive heart failure, prior transient ischemic attack/stroke/thromboembolism, vascular disease, 
chronic renal impairment, left atrial enlargement, chronic obstructive pulmonary disease and body 
mass index >30 kg/m2 compared to non-diabetic patients (Table 1). Patients receiving insulin 
showed higher percentages of congestive heart failure, vascular disease, chronic renal impairment, 
chronic obstructive pulmonary disease and body mass index >30 kg/m2  versus  those with non-
insulin requiring diabetes. Of note, in our study population only 18 patients had type 1 diabetes, 
with only one patient experiencing a thromboembolic event during the follow-up.  
We also evaluated the prevalence of different antithrombotic strategies in the various 
subgroups (Table 1). Compared with non-diabetic patients, those on insulin treatment had higher 
use of vitamin K antagonists (VKA) plus antiplatelet therapy (16.7% vs 9.6%, P=0.0002) at 
baseline and higher utilization of VKAs (71.5% vs 62.9%, P=0.0036) at one year. No 
antithrombotic therapy was less frequent in diabetic patients on insulin both at baseline and at one 
year (2.4% vs 6.4% in non-diabetic patients, P=0.0093 and 5.6% vs 9.6%, P=0.0238, respectively). 
Antithrombotic therapy was similar in diabetic patients with and without insulin, with the exception 
of a higher prevalence of VKAs plus an antiplatelet agent at baseline in the former (16.7% vs 
11.1%, P=0.0120). In the comparison between non-diabetic patients and diabetic patients not 
receiving insulin, the latter more frequently were given VKAs only at baseline (69.8% vs 66.2%, 
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P=0.030) and less frequently received antiplatelet treatment and no antithrombotic drug both at 
baseline and at 1 year.  
In the overall population, the incidence of stroke/systemic embolism at 1 year was 2.0 per 
100 patients/year. Insulin-requiring diabetes was associated with a higher risk of stroke/systemic 
embolism versus both no diabetes (5.2 per 100 patients/year vs 1.9 per 100 patients/year; HR 2.89, 
95% CI 1.67-5.02; P=0.0002) and non-insulin requiring diabetes (5.2 per 100 patients/year vs 1.8 
per 100 patients/year; HR 2.96, 1.49-5.87; P=0.0019) (Figure 2). Rates of stroke/systemic 
embolism were not different in patients with diabetes not receiving insulin and in non-diabetic 
patients (HR 0.97, 0.58-1.61; P=0.90).  Adjustment for potential confounders provided similar 
results (Table 2). After the addition of the various risk factors as covariates to the COX 
proportional hazard regression model, the correlation between diabetes on insulin therapy and the 
higher occurrence of thromboembolic events remained always significant, with HRs ranging from 
2.60 to 3.52 (Table 3). 
In the comparison between insulin-requiring diabetes and non-insulin requiring diabetes, out 
of 15 tested covariates, 2 had statistically significant interactions with the group; in particular, the 
relative increase of thromboembolic events related to insulin therapy was higher in patients with 
congestive heart failure (vs those without) and in patients receiving antithrombotic therapy at 
baseline. Conversely, the HR of the comparison of patients with no diabetes versus patients with 
non-insulin requiring diabetes remained consistently non-significant (Table 3).   
The prevalence of sustained (persistent or permanent) AF tended to be higher in patients on 
insulin treatment (80% vs 76% in diabetic patients not receiving insulin and 67% in patients without 
diabetes). However, adjustment for the type of AF did not change the overall study results; in 
particular, the HR of stroke/systemic embolism with insulin-requiring diabetes mellitus vs no 
diabetes was 2.83, 95% CI 1.60-5.03 (P=0.0004); the HR of stroke/systemic embolism with insulin-
requiring diabetes mellitus vs diabetes without insulin therapy was 2.98, 95% CI 1.48-6.02 
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(P=0.0023); and the HR of stroke/systemic embolism with non-insulin requiring diabetes mellitus 
vs no diabetes was 0.98, 95% CI 0.59-1.63 (P=0.94). 
We could collect additional patient-level data on diabetes duration, daily insulin dose, 
presence/absence of microvascular complications, and use of oral glucose-lowering agents in a 
subgroup of 344 diabetic patients (i.e., 27% of the overall diabetic study population). The risk 
profile of these 344 patients providing additional data on diabetes duration was similar to that of the 
remaining population of diabetic patients (age 73.3±9.2 vs 72.7± 8.6 years, P=0.31; female gender 
36% vs 37%, P=0.66; mean CHA2DS2-VASc score 4.7±1.6 vs 4.6±1.6, P=0.42). The duration of 
diabetes was higher in diabetic patients on insulin vs those not receiving insulin (12.8±8.2 yrs vs 
9.2±6.7 yrs; P=0.0003), but the HR of stroke/systemic embolism with insulin therapy, adjusted for 
duration of diabetes, remained significant (HR 8.72, 95% CI 2.89-26.33; P=0.0001).    
 The total daily insulin dose was similar in patients with vs without stroke/systemic 
embolism (37.8±9.9 IU vs 38.5±26.2 IU; P=0.22), and no relationship between insulin dose and the 
occurrence of thromboembolic events was observed (HR 1.00, 95% CI 0.98-1.02; P=0.94). We 
found a significantly higher risk of stroke/systemic embolism in patients with at least one 
microvascular complication of diabetes (retinopathy, neuropathy or nephropathy): HR 9.27, 95% CI 
2.07-41.41; P=0.0036. We also attempted an analysis of different therapies in non-insulin requiring 
diabetes (diet vs oral antidiabetic agents, or among various classes of oral antidiabetic drugs), but 
these analyses were precluded by the overall low rate of thromboembolic events observed in these 
subgroups.  
We also evaluated the risk of stroke/systemic embolism in patients without diabetes, with 
diabetes not receiving insulin and in those with insulin-requiring diabetes according to different 
subgroups, including: presence or absence of: female gender, age ≥75 years, congestive heart 
failure, systemic hypertension, previous transient ischemic attack/stroke, any vascular disease, 
chronic obstructive pulmonary disease, chronic renal impairment, body mass index >30 kg/m2, 
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CHA2DS2-VASc score >1, coronary artery disease, peripheral artery disease, use of anticoagulant 
therapy.  The highest incidence of thromboembolic events in patients with diabetes on insulin 
treatment and the absence of any significant difference in thromboembolic events in patients with 
diabetes without insulin treatment compared with those without diabetes were maintained across 
various subpopulations (Figure 3).  Of note, among patients with diabetes on insulin therapy, the 
rate of stroke/systemic embolism was even high in those receiving any anticoagulant therapy at 
baseline (5.1 per 100 patients/year vs  6.1 per 100 patients/year in those without anticoagulation); 
the increased incidence of thromboembolic complications in diabetic patients receiving insulin was 
irrespective of the use of anticoagulant therapy (patients receiving any anticoagulant treatment: 5.1 
per 100 patients/year in diabetic patients on insulin vs 1.6 per 100 patients/year in diabetic patients  
without insulin and 1.8 per 100 patients/year in non-diabetics; patients without anticoagulant 
therapy: 6.1 vs 3.5 vs 1.9 per 100 patients/year). 
A total of 4,354 patients had no diabetes or non-insulin requiring diabetes and a CHA2DS2-
VASc score >1; the occurrence of stroke/systemic embolism at 1 year in such patients was 2.0%. 
All patients with diabetes on insulin therapy had a CHA2DS2-VASc score >1 and showed an annual 
stroke/embolism rate of 5.2 per 100 patients/year (P=0.0005).   
 
DISCUSSION 
In this analysis of individual patients’ data from the prospective PREFER in AF registry we found 
that diabetic patients on insulin therapy have a significantly higher risk of stroke/systemic embolism 
at 1 year versus both non-diabetic patients and diabetic patients without insulin treatment, but also 
that diabetes not treated with insulin does not entail a significantly increased risk.  
The proportion of patients with diabetes in our population was 22.5%, of whom 22.4% were 
insulin-treated; this prevalence is similar to that observed in other contemporary registries on AF 
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patients (10). Of note, a 40% relative increase in the risk of development and progression of AF has 
been demonstrated in diabetic versus non-diabetic patients (11), and has been related to electrical 
and structural atrial remodeling, changes in the autonomic response, atrial inflammation and 
oxidative stress (12).  
A wide range (from 3.6% to 8.6%) of annual incidence of thromboembolic events has been 
reported in diabetic patients with AF (11,13); this large variability reflects differences in study 
designs, definitions of outcome measures, patients’ baseline risk profile, concomitant therapies and 
types of populations included. Previous large studies have found that AF patients with coexisting 
diabetes present a significantly higher risk of thromboembolic events compared to those without. In 
a previous meta-analysis on the topic, including 7 studies and >12,000 patients, a 70% relative 
increase in risk has been observed in diabetic patient (13). To date, however, no study had 
separately and independently quantified the annual rates of AF-related thromboembolic events in 
diabetic patients according to insulin treatment.  
The surprising and unexpected finding of our study is the strikingly similar incidence of 
thromboembolic events at 1 year in patients with diabetes but no insulin treatment compared with 
non-diabetic patients. The absence of increased risk of events in the former was consistent in the 
various analyses here performed even after adjustments for both clinical confounders and 
concomitant antithrombotic therapy. Of note, the events rate was similar in non-diabetic patients 
and in patients with diabetes not receiving insulin despite the latter having a higher thromboembolic 
risk profile (i.e., older age, higher prevalence of hypertension, congestive heart failure, previous 
cerebrovascular events, vascular disease, chronic renal failure). Thus, according to our data, the sole 
presence of diabetes does not imply an increased thromboembolic risk in AF patients. Conversely, 
diabetic patients receiving insulin had an approximately 2.5-fold higher risk of stroke or systemic 
embolism at 1 year compared both to patients without diabetes and to patients with non-insulin 
requiring diabetes. Of note, this higher risk was more pronounced between 6 months and 1 year of 
follow-up. A clustering of risk factors likely contributes to this heightened risk, since patients with 
Patti G. et al., JACC070116-2744N-R2, page 12 
 
diabetes on insulin treatment had a longer diabetes duration, as well as higher prevalence 
cardiovascular risk factors, congestive heart failure, chronic pulmonary disease and renal 
impairment than patients without diabetes or those with diabetes not requiring insulin. However, the 
association between insulin-requiring diabetes and thromboembolic events was independent of the 
type of AF and of other possible confounding factors here examined; this association was also 
maintained in various subgroups, including the subpopulation of patients receiving anticoagulant 
therapy.  
We observed no relationship of daily insulin dose and thromboembolic risk. We cannot 
exclude a type II error in these results, and it is possible that the daily doses of insulin – marking a 
diabetes of particular severity – could be related to outcomes in larger cohorts or with a longer 
follow-up. Of note, diabetic patients with microvascular complications (retinopathy, neuropathy or 
nephropathy) featured a significantly increased incidence of thromboembolic events. Importantly, 
however, the selectively increased thromboembolic risk of patients receiving insulin – with no 
apparent increase in risk in the other set of diabetic patients – was independent of all potential 
confounders from parameters collected in the PREFER in AF Registry here assessed, also including 
duration of diabetes (14).  
Similar data supporting a differential prognostic role of diabetes with vs without insulin 
therapy have been described in at least one other setting; in particular, an analysis from the SHIFT 
trial on patients with chronic systolic heart failure (15) showed no increased incidence of 
cardiovascular death or hospitalization for worsening heart failure in diabetic patients not receiving 
insulin compared to non-diabetic patients, and a significant 33% higher risk of this outcome 
measure in diabetic patients on insulin compared to those not on insulin. 
Therefore, according to our data, diabetes needing insulin therapy, rather than the presence 
of diabetes per se, appears to be an independent factor affecting the occurrence of AF-related 
stroke/systemic embolism during follow-up. Results of this study may thus expand and strengthen 
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observational data from certain investigations suggesting no overall increase of thromboembolic 
risk in diabetic patients (16-20); a different prevalence of patients receiving insulin (generally not 
reported in most studies) may at least in part explain the important variability in the reported annual 
rates of thromboembolic events among diabetic patients and the variable degree of increase in the 
thromboembolic risk by diabetes mellitus in the various studies. 
Several pathophysiological mechanisms may explain the findings of this study. In patients 
with diabetes mellitus there is a hypercoagulable state, and this is particularly evident and 
pronounced in those with long-lasting disease receiving insulin therapy. In the latter, an increase in 
platelet reactivity and platelet turnover has been described, with a consequently more pronounced 
platelet activation (21). Moreover, a high inflammatory status and oxidative stress cause endothelial 
dysfunction, with higher expression of adhesion molecules, reduced release of nitric 
oxide/prostacyclin and increased production of endothelin-1 (4,22-24). Diabetic patients on insulin 
treatment also show increased levels and/or activity of various coagulation factors, including tissue 
factor, factor VII, von Willebrand factor and fibrinogen, as well as enhanced thrombin generation 
(21,25,26). Finally, lower tissue-plasminogen activator (tPA) activity, higher levels of type 1 
plasminogen activator inhibitor (PAI-1) (27,28) and higher levels of incorporation of the C3 
complement component  in the clot (29) have been demonstrated in such patients, leading to 
impaired fibrin clot lysis. The presence of insulin treatment is therefore certainly a marker for more 
advanced disease. Insulin may however also called into play as triggering by itself some of the 
disease features, including atherosclerosis (30). While the precise mechanisms triggering changes in 
coagulation in diabetic patients receiving insulin therapy are not completely known, chronic 
exposure to high glucose levels, increased levels of advanced glycosylation end products, and also 
direct effects of exogenous insulin, providing pathologically high levels of insulin in the setting of 
insulin resistance, as occurring in all type 2 diabetic patients receiving insulin, are all possibly 
involved (30,31).    
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This work has strengths in being a prospective analysis on AF patients who received a 
complete baseline assessment and underwent a planned follow-up visit at 1 year with accurate 
evaluation of the outcome measures. Limitations are that we could not establish the 
thromboembolic risk of the untreated population included, or the risk in relation to specific 
antithrombotic therapies. However, the crude increase in thromboembolic risk occurred in the 
presence of insulin-requiring diabetes is probably even higher than that detected in our 
investigation: in fact, patients on insulin had a higher prevalence of VKA use and less frequently 
received no antithrombotic drug than those without diabetes, while they more often were given 
VKAs plus antiplatelet drugs than those with diabetes without insulin. Thus, it is unlikely that we 
overestimated the risk of insulin-requiring diabetic patients in our study. Furthermore, residual 
confounding cannot be excluded and, due to the size of the population, we could not stratify the 
thromboembolic risk of diabetic patients on insulin therapy according to different CHA2DS2-VASc 
scores (score 1 versus >1). The issue of whether the relationship between the type of diabetes and 
thromboembolic risk was irrespective of the duration of diabetes was evaluated in approximately ¼ 
of the diabetic population within PREFER in AF (344 patients, 27%), representative of the entire 
original cohort of diabetic patients; in this subset, the HR of stroke/systemic embolism in patients 
with insulin therapy, compared with patients not on insulin, when adjusted for the duration of 
diabetes, remained significant. Therefore, main results of this sensitivity analysis continue to 
support one main conclusion of the paper, that insulin-requiring diabetes is a much worse condition 
than non-insulin requiring diabetes. Importantly, the risk profile of those 344 patients providing 
additional data on diabetes duration was similar to that of the remaining population of diabetic 
patients. We can therefore reasonably assume that the results of this further analysis were not 
affected by the selection of patients, and no bias was introduced in this secondary analysis.  Finally, 
a non-uniform definition of diabetes mellitus might have been used in the study population 
according to local practices, and – more important – we have no data on the specific criteria for 
initiating insulin therapy and on glycemic control during follow-up. However, we consider unlikely 
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that use of non-uniform definitions of diabetes and criteria for initiating insulin therapy may have 
affected the study results, inasmuch as the physicians in the Western European countries 
participating in PREFER in AF are generally accustomed to contemporary, international guidelines 
for defining diabetes and initiating insulin treatment. Any such limitations should not however 
affect the main finding of our study, which is not only the higher risk of the insulin-requiring 
diabetes, likely clustering with a higher severity of diabetes, but rather the very low risk of non-
insulin-requiring diabetes. This indicates for the first time a quite dichotomous behavior of the 
diabetic AF population as to thromboembolic risk according to the use or lack of use of insulin. Of 
note, results of our investigation apply essentially to patients with type 2 diabetes, who represented 
98.6% of the diabetic population included, and it may be that insulin provision in type 1 diabetes, in 
the absence of insulin resistance, is not associated with increased thromboembolic risk. 
In conclusion, our findings robustly indicate that insulin-requiring diabetes, essentially type 
2 diabetes, largely contributes to the overall increase of thromboembolic risk in AF; while the mere 
presence of diabetes without insulin treatment does not apparently convey a negative prognostic 
value. Such findings have implications in the assessment of thromboembolic risk in the AF 
population with diabetes and might have therapeutic implications, which need however to be 
explored in further dedicated intervention studies. 
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FIGURE LEGENDS 
 
Figure 1. Flow diagram indicating patients’ disposition in the present study, leading to the final 
number of 5,717 patients here included.  
 
Figure 2. Kaplan-Meier curves for incidence of stroke/systemic embolism according to diabetes 
status. DM= Diabetes mellitus; SEE= Systemic embolic events 
 
Figure 3. Stroke or systemic embolism by subpopulations. CHA2DS2-VASc score ≤1 is 'female 
gender-corrected' (i.e. CHA2DS2-VASc ≤1 for males and CHA2DS2-VASc ≤2 for females).  
AP= Antiplatelet; BL= Baseline; BMI= Body mass index; CHD= Coronary heart disease; CHF= 
Congestive heart failure; COPD= Chronic obstructive pulmonary disease; CRI= Chronic renal 
impairment; Hyp= Systemic hypertension; NOAC= Non-vitamin K antagonist oral anticoagulants; 
PAD= Peripheral artery disease; SEE= Systemic embolic events; TIA= Transient ischemic attack; 
VKA= vitamin K antagonists 
 
 
Table 1. Main demographic/clinical characteristics in the study population according to diabetes status.  
 
Variable No DM 
 
 
     N=4,429 
Non-insulin 
requiring DM 
 
N=1,000 
Insulin-
requiring DM 
 
N=288 
P value 
No DM vs non-
insulin requiring DM 
 
 
P value 
No DM vs 
insulin-requiring 
DM  
 
 
P value 
Non-insulin requiring DM 
vs insulin-requiring DM 
 
Age 65-74 yrs 
 
1,431 (32.3) 
 
384 (38.4) 
 
97 (33.7) 
 
0.0002 
 
0.63 
 
0.15 
 
Age ≥75 yrs 1,941 (43.8) 453 (45.3) 137 (47.6) 0.40 0.22 0.50 
 
Female gender 1,782 (40.2) 373 (37.3) 104 (36.1) 0.09 0.17 0.71 
 
BMI >30 kg/m2 1,089 (25.3) 377 (38.2) 133 (47.0) <0.0001 <0.0001 0.0079 
 
Systemic hypertension 2,998 (67.7) 852 (85.2) 255 (88.5%) <0.0001 <0.0001 0.15 
 
Congestive heart failure 1,146 (25.9) 342 (34.2) 164 (56.9) <0.0001 <0.0001 <0.0001 
 
Prior TIA/stroke/thromboembolism 635 (14.3) 192 (19.2) 67 (23.3) 0.0001 <0.0001 0.13 
 
Vascular disease 846 (19.1) 295 (29.5) 133 (46.2) <0.0001 <0.0001 <0.0001 
 
Chronic renal impairment  
(Cr Cl <30 mL/min/1.73 m2 ) 
484 (11.1) 173 (17.7) 100 (36.4) 0.0001 <0.0001 <0.0001 
 
Left atrial enlargement 
(antero-posterior diameter >40 mm) 
 
2,529 (69.2) 650 (78.2) 190 (79.2) <0.0001 0.0013 0.7532 
 
Chronic obstructive pulmonary disease  434 (9.9) 131 (13.3) 62 (21.7) 0.0016 <0.0001 0.0005 
 
Antithrombotic therapies at baseline       
NOAC 281 (6.3) 77 (7.7) 13 (4.5) 0.1192 0.2154 0.0648 
VKA only 2933 (66.2) 698 (69.8) 194 (67.4) 0.0300 0.6943 0.4295 
Antiplatelet only 505 (11.4) 82 (8.2) 26 (9.0) 0.0034 0.2183 0.6553 
VKA plus antiplatelet  427 (9.6) 111 (11.1) 48 (16.7) 0.1634 0.0002 0.0120 
No therapy 283 (6.4) 32 (3.2) 7 (2.4) 0.0001 0.0093 0.5036 
       
Antithrombotic therapies at one year       
NOAC 576 (13.0) 152 (15.2) 32 (11.1) 0.0661 0.3533 0.0821 
VKA only 2788 (62.9) 662 (66.2) 206 (71.5) 0.0538 0.0036 0.0897 
Antiplatelet only 384 (8.7) 54 (5.4) 9 (3.1) 0.0007 0.0017 0.1193 
VKA plus antiplatelet  255 (5.8) 62 (6.2) 25 (8.7) 0.5900 0.0435 0.1413 
No therapy 426 (9.6) 70 (7.0) 16 (5.6) 0.0098 0.0238 0.3881 
 
Values are given as N (%). BMI= Body mass index; DM= Diabetes mellitus; NOAC= non-vitamin K antagonist oral anticoagulants; TIA= 
Transient ischemic attack; VKA= vitamin K antagonists  
 
Table 2. Adjusted risk of stroke/systemic embolic events at one year * 
Comparison HR 95% CI P value 
Insulin-requiring diabetes vs no diabetes  
 
2.19 1.21-3.94 0.009 
Insulin-requiring diabetes vs non-insulin requiring diabetes  
 
2.61 1.26-5.43 0.01 
Non-insulin requiring diabetes vs no diabetes  0.93 0.55-1.58 0.80 
*Adjusted for congestive heart failure,  systemic hypertension, age >75 yrs, prior stroke/transient ischemic attack/thromboembolism,  
vascular disease, female gender, chronic obstructive pulmonary disease, chronic renal impairment, body mass index  >30 kg/m2,  
CHA2DS2-VASc score 0-1, type of atrial fibrillation, vitamin K antagonist therapy, use of non-vitamin K antagonist oral anticoagulants, vitamin K antagonist plus antiplatelet therapy  
 
. 
 
Table 3. COX Proportional Hazard Regression Model including various clinical characteristics as 
covariates. 
 HR 95% CI P value Interaction P 
value 
Insulin-requiring diabetes vs non-
insulin requiring diabetes  
 
2.96 1.49-5.87 0.0019  
Congestive heart failure 2.60 1.28-5.25 0.0079 0.13 
Systemic hypertension 2.92 1.47-5.81 0.0022 0.47 
Age ≥75 yrs 2.92 1.47-5.80 0.0022 0.18 
Previous transient ischemic 
attack/stroke/thromboembolism  
2.87 1.45-5.70 0.0026 0.08 
Vascular disease 3.11 1.55-6.23 0.0014 0.42 
Age 65-74 yrs 2.92 1.47-5.80 0.0022 0.46 
Female gender 2.96 1.49-5.88 0.0019 0.76 
Left atrial enlargement 3.52 1.63-7.58 0.0014 0.11 
Chronic obstructive pulmonary disease 2.60 1.30-5.19 0.0068 0.0008 
Chronic renal impairment  2.82 1.40-5.66 0.0036 0.72 
BMI >30 kg/m2 3.19 1.59-6.40 0.0011 0.58 
No anti-thrombotic therapy at baseline 3.05 1.54-6.06 0.0015 0.0027 
VKA therapy at baseline 2.98 1.50-5.92 0.0018 0.37 
Antiplatelet therapy at baseline 2.97 1.50-5.89 0.0019 0.60 
VKA + antiplatelet therapy at baseline 
 
3.07 1.54-6.10 0.0014 0.21 
 
Non-insulin requiring diabetes vs no 
diabetes  
 
0.97 0.58-1.61 0.90  
Congestive heart failure 0.89 0.53-1.48 0.65 <0.0001 
Systemic hypertension 0.99 0.59-1.66 0.97 0.55 
Age ≥75 yrs 0.96 0.58-1.60 0.88 0.011 
Previous transient ischemic 
attack/stroke/thromboembolism  
0.92 0.55-1.54 0.75 0.0002 
Vascular disease 0.96 0.58-1.60 0.88 0.80 
Age 65-74 yrs 0.99 0.59-1.64 0.95 0.14 
Female gender 0.98 0.59-1.63 0.94 0.02 
Left atrial enlargement 0.82 0.45-1.48 0.50 0.33 
Chronic obstructive pulmonary disease 0.95 0.57-1.59 0.86 0.07 
Chronic renal impairment  0.96 0.58-1.60 0.87 0.41 
BMI >30 kg/m2 0.94 0.56-1.60 0.83 0.68 
No anti-thrombotic therapy at baseline 0.97 0.58-1.62 0.92 0.65 
VKA therapy at baseline 0.97 0.59-1.62 0.92 0.33 
Antiplatelet therapy at baseline 0.97 0.58-1.62 0.91 0.72 
VKA + antiplatelet therapy at baseline 
 
0.97 0.58-1.62 0.91 0.48 
BMI= Body mass index; VKA= Vitamin K antagonist 



